• LevelJump will issue up to 13,333,333 units at $0.15 per unit for gross proceeds of up to $2,000,000
  • Net proceeds from the financing will be used towards acquisitions and for general working capital purposes
  • The offering is expected to close in April
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are unchanged on the day, trading at C$0.15 per share at 1:45 pm ET

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement for gross proceeds of up to $2,000,000.

The company will issue up to 13,333,333 units at $0.15 per unit. Each unit will consist of one common share and one common share purchase warrant.  Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 with an expiry date of March 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in April.

Securities issued will be subject to a four-month hold period in accordance with applicable securities laws.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are unchanged on the day, trading at C$0.15 per share at 1:45 pm ET.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.